Felix Bokstein

List of Publications by Year
in descending order

84 papers	2,648 citations	186209 28 h-index	189801 50 g-index
84 all docs	84 docs citations	84 times ranked	3978 citing authors

#	Article	IF	Citations
1	Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood, 2010, 115, 5005-5011.	0.6	325
2	Leptomeningeal metastases from solid tumors. Cancer, 1998, 82, 1756-1763.	2.0	157
3	In vivo assessment of the window of barrier opening after osmotic blood–brain barrier disruption in humans. Journal of Neurosurgery, 2000, 92, 599-605.	0.9	149
4	Treatment with bevacizumab and irinotecan for recurrent high‐grade glial tumors. Cancer, 2008, 112, 2267-2273.	2.0	144
5	Progressive low-grade oligodendrogliomas. Cancer, 2006, 106, 1759-1765.	2.0	131
6	Neurologic complications of immune checkpoint inhibitors. Journal of Neuro-Oncology, 2018, 137, 601-609.	1.4	126
7	Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. Journal of Clinical Oncology, 2016, 34, 1620-1625.	0.8	121
8	Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. Journal of Neuro-Oncology, 2016, 129, 453-460.	1.4	82
9	Malignant involvement of the spine: assessment by 18F-FDG PET/CT. Journal of Nuclear Medicine, 2004, 45, 279-84.	2.8	78
10	MRI radiomics analysis of molecular alterations in low-grade gliomas. International Journal of Computer Assisted Radiology and Surgery, 2018, 13, 563-571.	1.7	72
11	Central Nervous System Relapse of Systemic Non-Hodgkin's Lymphoma: Results of Treatment Based on High-dose Methotrexate Combination Chemotherapy. Leukemia and Lymphoma, 2002, 43, 587-593.	0.6	63
12	Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: A longitudinal MRI study. European Journal of Radiology, 2014, 83, 1250-1256.	1.2	63
13	Delayed initiation of radiotherapy for glioblastoma: how important is it to push to the front (or the) Tj ETQq1 1 0.784314 rgBT /Overlock	1.4	59
14	Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: A multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma. International Journal of Oncology, 2015, 46, 1883-1892.	1.4	57
15	Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. Clinical Pharmacology and Therapeutics, 2000, 67, 631-641.	2.3	55
16	NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. Journal of Neuro-Oncology, 2017, 131, 193-199.	1.4	55
17	Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. Journal of Neuro-Oncology, 2006, 79, 153-157.	1.4	53
18	Assessment of neurolymphomatosis by brachial plexus biopsy and PET/CT. Report of a case. Journal of Neuro-Oncology, 2005, 72, 163-167.	1.4	50

#	Article	IF	Citations
19	Changes in cerebral metabolism during ketogenic diet in patients with primary brain tumors: 1H-MRS study. Journal of Neuro-Oncology, 2017, 132, 267-275.	1.4	50
20	Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. Neuro-Oncology, 2013, 15, 936-944.	0.6	48
21	A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). Neuro-Oncology, 2020, 22, 705-717.	0.6	47
22	The impact of enrollment in clinical trials on survival of patients with glioblastoma. Journal of Clinical Neuroscience, 2012, 19, 1530-1534.	0.8	43
23	Classification of tumor area using combined DCE and DSC MRI in patients with glioblastoma. Journal of Neuro-Oncology, 2015, 121, 349-357.	1.4	37
24	Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients. Journal of Neuro-Oncology, 2016, 130, 211-219.	1.4	35
25	Classification of High-Grade Glioma into Tumor and Nontumor Components Using Support Vector Machine. American Journal of Neuroradiology, 2017, 38, 908-914.	1.2	35
26	Differentiation between vasogenic edema and infiltrative tumor in patients with high‑grade gliomas using texture patch‑based analysis. Journal of Magnetic Resonance Imaging, 2018, 48, 729-736.	1.9	34
27	Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. Neuro-Oncology, 2018, 20, 966-974.	0.6	33
28	Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study. Frontiers in Oncology, 2020, 10, 411.	1.3	33
29	Differentiation between treatment-related changes and progressive disease in patients with high grade brain tumors using support vector machine classification based on DCE MRI. Journal of Neuro-Oncology, 2016, 127, 515-524.	1.4	30
30	Hemodynamic Response Imaging: A Potential Tool for the Assessment of Angiogenesis in Brain Tumors. PLoS ONE, 2012, 7, e49416.	1.1	28
31	Radiotherapy for spinal cord compression in patients with soft-tissue sarcoma. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1468-1473.	0.4	27
32	Automatic multi-modal MR tissue classification for the assessment of response to bevacizumab in patients with glioblastoma. European Journal of Radiology, 2013, 82, e87-e94.	1.2	26
33	Stereotactic radiosurgery (SRS) in high-grade glioma: judicious selection of small target volumes improves results. Journal of Neuro-Oncology, 2016, 126, 551-557.	1.4	24
34	Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study. Neuro-Oncology, 2020, 22, 694-704.	0.6	23
35	The effect of parental age on the presence of de novo mutations â€" Lessons from neurofibromatosis type I. Molecular Genetics & Genomic Medicine, 2016, 4, 480-486.	0.6	21
36	The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?. Journal of Neuro-Oncology, 2016, 127, 493-502.	1.4	21

#	Article	IF	Citations
37	Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade Gliomas. American Journal of Neuroradiology, 2016, 37, 2003-2009.	1.2	18
38	Optic Pathway Gliomas in Adults. Neurosurgery, 2014, 74, 273-280.	0.6	17
39	Surgical Therapies in Brain Metastasis. Seminars in Oncology, 2007, 34, 197-205.	0.8	16
40	Human cerebral blood volume measurements using dynamic contrast enhancement in comparison to dynamic susceptibility contrast MRI. Neuroradiology, 2015, 57, 671-678.	1.1	16
41	Spinal and Paraspinal Plexiform Neurofibromas in Patients with Neurofibromatosis Type 1: A Novel Scoring System for Radiological-Clinical Correlation. American Journal of Neuroradiology, 2017, 38, 1869-1875.	1.2	15
42	Interreader Variability of Dynamic Contrast-enhanced MRI of Recurrent Glioblastoma: The Multicenter ACRIN 6677/RTOG 0625 Study. Radiology, 2019, 290, 467-476.	3.6	15
43	Calcification in high grade gliomas treated with bevacizumab. Journal of Neuro-Oncology, 2015, 123, 283-288.	1.4	14
44	Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab. World Neurosurgery, 2018, 110, e727-e737.	0.7	14
45	Monitoring Brain Tumor Vascular Heamodynamic following Anti-Angiogenic Therapy with Advanced Magnetic Resonance Imaging in Mice. PLoS ONE, 2014, 9, e115093.	1.1	9
46	Repeatability of dynamic contrast enhanced vp parameter in healthy subjects and patients with brain tumors. Journal of Neuro-Oncology, 2018, 140, 727-737.	1.4	9
47	Gliomas of the posterior fossa in adults. Journal of Neuro-Oncology, 2013, 115, 401-409.	1.4	8
48	Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience. Targeted Oncology, 2018, 13, 217-226.	1.7	8
49	A Common Sense Approach to Radiotherapy Planning of Glioblastoma Multiforme Situated in The Temporal Lobe. International Journal of Radiation Oncology Biology Physics, 2008, 72, 900-904.	0.4	7
50	Does streaming affect the cerebral distribution of infraophthalmic intracarotid chemotherapy?. American Journal of Neuroradiology, 2002, 23, 1732-5.	1.2	7
51	Optimization of DCE-MRI protocol for the assessment of patients with brain tumors. Magnetic Resonance Imaging, 2016, 34, 1242-1247.	1.0	6
52	Surgical Management of â€œKissingâ€•Spinal Plexiform Neurofibromas in Neurofibromatosis Type 1 Patients. World Neurosurgery, 2020, 134, e1143-e1147.	0.7	6
53	Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients. Journal of Neuro-Oncology, 2021, 151, 211-220.	1.4	5
54	Mechanisms of post-radiation injury: cerebral microinfarction not a significant factor. Journal of Neuro-Oncology, 2017, 131, 277-281.	1.4	4

#	Article	IF	Citations
55	Ofranogene obadenovec (VB-111), an anti-cancer gene therapy in combination with bevacizumab to improve overall survival compared to bevacizumab monotherapy in patients with rGBM: A phase 2 historically controlled trial.. Journal of Clinical Oncology, 2016, 34, 2074-2074.	0.8	3
56	IMCT-01PEMBROLIZUMAB: FIRST EXPERIENCE WITH RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. Neuro-Oncology, 2015, 17, v107.1-v107.	0.6	2
57	Cranial irradiation in childhood mimicking neurofibromatosis type II. American Journal of Medical Genetics, Part A, 2017, 173, 1635-1639.	0.7	2
58	Leptomeningeal metastases from solid tumors. , 1998, 82, 1756.		2
59	Trial To Survive. Neurosurgery, 2009, 65, 425.	0.6	1
60	BMET-26PHASE 2 STUDY OF VB-111, AN ANTI-CANCER GENE THERAPY, AS MONOTHERAPY FOLLOWED BY COMBINATION OF VB-111 WITH BEVACIZUMAB, IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v50.4-v51.	0.6	1
61	ACTR-46. TUMOR TREATING FIELDS COMBINED WITH RADIOTHERAPY AND TEMOZOLOMIDE FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA: FINAL RESULTS FROM A PILOT STUDY. Neuro-Oncology, 2019, 21, vi23-vi24.	0.6	1
62	Verification of statistical oncological endpoints on encrypted data: Confirming the feasibility of real-world data sharing without the need to reveal protected patient information.. Journal of Clinical Oncology, 2021, 39, e18725-e18725.	0.8	1
63	RTID-12. PHASE 2 TRIAL OF TUMOR TREATING FIELDS (TTFIELDS) PLUS RADIATION THERAPY (RT) PLUS TEMOZOLAMIDE (TMZ) COMPARED TO RT PLUS TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA (ndGBM). Neuro-Oncology, 2020, 22, ii196-ii196.	0.6	1
64	Abstract CT206: Concurrent Tumor Treating Fields (TTFields) and radiation therapy for newly diagnosed glioblastoma: A safety and feasibility study. , 2020, , .		1
65	Molecular profiling-selected treatment in metastatic gastric and oesophageal cancer: Real-life clinical experience.. Journal of Clinical Oncology, 2017, 35, e15537-e15537.	0.8	1
66	Abstract CT203: Randomized Phase II trial of Tumor Treating Fields plus radiation therapy plus temozolamide compared to radiation therapy plus temozolomide in patients with newly diagnosed glioblastoma. , 2019, , .		1
67	Antiangiogenesis in recurrent glioblastoma: proof of principle. Neurology International, 2009, 1, e21.	0.2	1
68	BIOM-22. RELEVANCE OF TUMOR MUTATION BURDEN (TMB) IN HIGH-GRADE GLIOMAS. Neuro-Oncology, 2021, 23, vi15-vi15.	0.6	1
69	Painful paroxysmal dystonia associated with focal epileptic activity.. Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 257-258.	0.9	0
70	RTRB-03SHORT DELAY IN INITIATION OF RADIOTHERAPY WITH CONCURRENT CHEMOTHERAPY FOR GLIOBLASTOMA: A SECONDARY ANALYSIS OF NRG ONCOLOGY/RTOG 0525 AND 0825. Neuro-Oncology, 2015, 17, v195.3-v195.	0.6	0
71	RTRB-11MULTIPLE BRAIN METASTASES TREATED WITH SINGLE-ISOCENTER LINAC-BASED STEREOTACTIC RADIOSURGERY (SRS). Neuro-Oncology, 2015, 17, v197.3-v197.	0.6	0
72	NIMG-47. MACHINE LEARNING ALGORITHMS FOR PREDICTING GBM GROWTH PATTERNS USING ADVANCED AND DELAYED-CONTRAST MRI: FEASIBILITY DEMONSTRATION. Neuro-Oncology, 2016, 18, vi135-vi135.	0.6	0

#	Article	IF	Citations
73	RARE-29. HIGH-DOSE METHOTREXATE (HD MTX)-BASED TREATMENTS OF PRIMARY CNS LYMPHOMA: OPTIMAL DOSE REVISITED - AÂRETROSPECTIVE ANALYSIS OF OUTCOMES IN TERTIARY MEDICAL CENTER. Neuro-Oncology, 2016, 18, vi166-vi166.	0.6	0
74	ATIM-03. BIOMARKER ANALYSIS SUPPORTS THE VB-111 DUAL MECHANISM OF ACTION. Neuro-Oncology, 2017, 19, vi26-vi26.	0.6	0
75	NTOX-13. NEUROLOGIC COMPLICATIONS OF IMMUNE CHECKPOINT INHIBITORS. Neuro-Oncology, 2017, 19, vi167-vi167.	0.6	0
76	NIMG-36. THE SIGNIFICANCE OF PUNCTATE CONTRAST-ENHANCING LESIONS IN TREATED HIGH GRADE GLIOMA. Neuro-Oncology, 2018, 20, vi183-vi184.	0.6	0
77	INNV-30. TUMOR TREATING FIELDS AND RADIOTHERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA: SAFETY AND EFFICACY RESULTS FROM A PILOT STUDY. Neuro-Oncology, 2018, 20, vi144-vi144.	0.6	0
78	COMP-18. MACHINE LEARNING DIFFERENTIATION BETWEEN PLEXIFORM NEUROFIBROMAS AND MALIGNANT NERVE SHEATH TUMORS IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1) BASED ON MRI. Neuro-Oncology, 2018, 20, vi67-vi67.	0.6	0
79	HOUT-28. CLINICAL EXPERIENCE WITH TUMOR TREATING FIELDS (TTFIELDS, OPTUNEÂ®) IN ISRAEL - PATIENT ACCEPTANCE AND SAFETY. Neuro-Oncology, 2018, 20, vi119-vi119.	0.6	0
80	NIMG-35. TREATMENT RESPONSE ASSESSMENT MAPS (TRAMs) SENSITIVITY TO TUMOR/TREATMENT-EFFECTS AS A FUNCTION OF DATA ACQUISITION PARAMETERS. Neuro-Oncology, 2018, 20, vi183-vi183.	0.6	0
81	Comprehensive genomic profiling of primary intracranial malignant neoplasms to reveal frequency of clinically relevant genomic alterations.. Journal of Clinical Oncology, 2015, 33, e13007-e13007.	0.8	0
82	Abstract CT008: Tumor Treating Fields combined with radiotherapy and temzolomide for newly diagnosed glioblastoma: Final results from a pilot study. , 2019, , .		0
83	Updated safety/feasibility study of concurrent tumor treating fields (TTFields) and radiation therapy for newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2020, 38, e14535-e14535.	0.8	0
84	NIMG-05. DIFFERENCES IN VASCULARITY BETWEEN RECURRENT GLIOBLASTOMA AND BRAIN METASTASIS USING DYNAMIC CONTRAST ENHANCED MRI. Neuro-Oncology, 2021, 23, vi128-vi128.	0.6	0